PANDEMIC RESPONSE
generally meaning they can be taken orally. PLA2 is associated with inflamma- tion, other impairments and destruction in the lung, characteristic of acute respiratory distress syndrome. COVID-19 is one of several diseases that results in acute respi- ratory distress syndrome, which leads to the degradation of lung function, inad- equate oxygen supply and frequently, severe long-term breathing problems and even death.
EMERGENCY USE AUTHORIZATION
The BioFire Defense COVID-19 test was authorized for emergency use on March 23 by the FDA. The test is performed on the BioFire FilmArray instrument, which is already present in many DOD facilities. (Photo courtesy of BioFire Defense)
Together with the industry partner, Ophi- rex, Inc., WPAC PMO is working to develop varespladib as an acute respiratory distress syndrome preventative and treat- ment for COVID-19 patients. Te intent of drug treatment is minimized hospital- ization, critical care treatment and survival of COVID-19 patients. While PLA2 is a major component of snake venom, humans also produce PLA2. For us, it acts in a pro-inflammatory cascade and in disintegration of lung surfactant, a protec- tive layer that prevents fluid retention in the lungs. PLA2 inhibition is therefore hypothesized to reduce inflammation and protect or restore surfactant to aid lung function.
The three WPAC projects selected to receive Tier 1 acquisition program invest- ments are:
Te phospholipase A2 (PLA2) inhibitor, varespladib, for SARS-CoV-2-related acute respiratory distress syndrome treatment. Acute respiratory distress syndrome is marked by inflammation and fluid build- up that diminishes oxygen supply and causes lung dysfunction.
FDA approval of the BioFire Defense COVID-19 test using the statutory 510(k) pathway with Sample Type Expansion under emergency use authorization. Te 510(k) pathway is one mechanism for attaining FDA approval.
The SARS-CoV-2 Rapid Diagnos- tic Lateral Flow Tests for direct antigen detection and serology. A lateral flow diag- nostic test is essentially a "test strip" where a patient sample and sample buffer, liquid, is applied to one end of the strip, which then indicates a positive or negative result.
PLA2 Inhibitor for SARS-CoV-2-related acute respiratory distress syndrome— varespladib
Te secreted PLA2, varespladib, for SARS- CoV-2-related acute respiratory distress syndrome treatment is a small-molecule drug that dampens activity of the molecule called phospholipase A2. Small-mole- cule drugs have a low molecular weight,
“This test detects SARS-CoV-2
nucleic acid with a high degree of specificity and sensitivity. The virus can’t hide from this test.”
https://asc.ar my.mil 47
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176
